Strategic IP leverage TRS possesses a strong IP position with an extensive patent portfolio and trade secrets around 3D printed resorbable scaffolds and the Affinity coating, suggesting opportunities to engage with OEMs and large implant manufacturers seeking differentiated coatings and scaffolds.

FDA cleared assets Both the 3D printed resorbable scaffold and the Affinity coating have FDA 510(k) clearance, enabling near-term discussions with medical device companies for licensing, co-development, or acquisition of commercial-ready tech.

Manufacturing readiness TRS operates an independent FDA-compliant manufacturing facility with a certified cleanroom capable of scaling to commercial volumes, making it feasible to partner on high-volume production or contract manufacturing for partner devices.

Clinical and research validation Extensive university, NIH, and company-sponsored research over a decade underpins the platform, providing a credible foundation for partnerships with academic centers, hospitals, and biotech firms pursuing regenerative solutions.

Acquisition and asset opportunity Past sale of 3D printing assets to DePuy Synthes signals a potential openness to collaboration or sale/partial license of technology or manufacturing capabilities with established medical device players seeking accelerated time-to-market.